ASCO 2016 | Targeted therapy for advanced solid tumors based on molecular profiles: early results from MyPathway
Press brief by John Hainsworth, MD of the Sarah Cannon Research Institute, Nashville, TN, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
Get great new content delivered to your inboxSign up
Producing patient-specific tumor-reactive T-cells
TNBC treatment: platinum-based therapy and PARP inhibition
BROCADE3: veliparib with carboplatin/paclitaxel in HER2-/BRCA+ advanced breast cancer
Health-related QoL in ipilimumab treated advanced melanoma survivors
OpACIN and OpACIN-neo trial updates